(19)
(11) EP 4 031 139 A1

(12)

(43) Date of publication:
27.07.2022 Bulletin 2022/30

(21) Application number: 20775718.8

(22) Date of filing: 14.09.2020
(51) International Patent Classification (IPC): 
A61K 31/506(2006.01)
A61P 35/00(2006.01)
 A61K 31/519(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/519; A61K 31/506; A61P 35/00
 
C-Sets:
  1. A61K 31/519, A61K 2300/00;
  2. A61K 31/506, A61K 2300/00;
(86) International application number:
PCT/IB2020/058515
(87) International publication number:
WO 2021/053489 (25.03.2021 Gazette 2021/12)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 16.09.2019 US 201962900931 P

(71) Applicant: Novartis AG
4056 Basel (CH)

(72) Inventors:
  • ELIASSON, Asa
    4002 Basel (CH)
  • GUERREIRO, Nelson
    4002 Basel (CH)
  • MEILLE, Christophe
    4002 Basel (CH)
  • MENSSEN, Hans
    4002 Basel (CH)
  • WROCLAWSKA, Monika
    4002 Basel (CH)
  • VANASSE, K Gary J
    Cambridge, Massachusetts 02139 (US)

(74) Representative: Ridout, Joseph 
Novartis Pharma AG Patent Department Lichtstrasse 35
4056 Basel
4056 Basel (CH)

   


(54) USE OF AN MDM2 INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS